Aleks Engel Ph.D Overview

  • Primary Position
  • Partner, Planeta...

  • Primary Industry
  • Healthcare

  • Active Board Seats
  • 2

  • Med. Deal Size

  • Med. Valuation

Aleks Engel Ph.D General Information

Biography

Dr. Aleks Engel serves as Partner, Planetary Health Investments at Novo Holdings. Prior to joining Novo Holdings, Dr. Engel was employed as VP in Baxter International in Illinois and Shanghai, working with global M&A licensing, growth strategies, investment prioritization and go-to-market planning. Other previous employments include Pfizer Global Research and Development, Thomson Scientific & Healthcare and McKinsey & Company (all U.S.A.). Aleks holds a PhD in Biochemical Engineering and a MSc in Chemical Engineering Practice from Massachusetts Institute of Technology.

Contact Information

Primary Position
Partner, Planetary Health Investments, Novo Holdings
Education
Massachusetts Institute of Technology (MIT), Ph.D. (Doctor of Philosophy)
MIT (Sloan), Degree
Massachusetts Institute of Technology (MIT), MS (Master of Science)
Georgia Tech University, BS (Bachelor of Science)
Gender
Male
Phone
+45 35
Address
  • Tuborg Havnevej 19
  • 2900
  • 2900 Hellerup
  • Denmark
+45 35

Aleks Engel Ph.D Positions (1)

Firm name Firm type Title Location Industry Since
Novo Holdings Investor Partner, Planetary Health Investments Hellerup, Denmark Corporate Venture Capital

Aleks Engel Ph.D Board Seats (2)

Company Industry Ownership Status Financing Status Location Since
Bactolife Biotechnology Privately Held (backing) Venture Capital-Backed Copenhagen, Denmark
Symphogen Biotechnology Acquired/Merged (Operating Subsidiary) Formerly VC-backed Ballerup, Denmark

Aleks Engel Ph.D Lead Partner on Deals (10)

Aleks Engel Ph.D has been the lead partner on 10 deals. Their latest deal was with Benchmark Genetics, a aquaculture company. The deal was made for on 25-Nov-2024.

Company Deal Date Deal Type Deal Size Deal Status Industry Location
Benchmark Genetics 25-Nov-2024 Merger/Acquisition Announced/In Progress Aquaculture Bergen, Norway
Revagenix 05-Jan-2024 Completed Drug Discovery San Francisco, CA
Paratek Pharmaceuticals 21-Sep-2023 Completed Pharmaceuticals King of Prussia, PA
Bactolife 08-Aug-2023 Completed Biotechnology Copenhagen, Denmark
AFYX Therapeutics 24-Jun-2019 Completed Drug Delivery Copenhagen, Denmark
Symphogen 22-Oct-2015 Completed Biotechnology Ballerup, Denmark
Symphogen 08-Jan-2006 Completed Biotechnology Ballerup, Denmark
Symphogen 02-Nov-2004 Completed Biotechnology Ballerup, Denmark
Symphogen 23-Jan-2002 Early Stage VC (Series A) Completed Biotechnology Ballerup, Denmark
Symphogen 01-Jan-2000 Seed Round Completed Biotechnology Ballerup, Denmark

Aleks Engel Ph.D Network (154)

Board Members (40)

Name Company Representing Location From
Jens Hansen Ph.D AFYX Therapeutics AFYX Therapeutics Copenhagen, Denmark
Steen Riisgaard Xellia Pharmaceuticals Novo Holdings Copenhagen, Denmark
Xellia Pharmaceuticals Self Copenhagen, Denmark
Xellia Pharmaceuticals Self Copenhagen, Denmark
Symphogen Gilde Healthcare Ballerup, Denmark

Portfolio Executives (66)

Name Company Role Deal date Location
Malcolm Pye Benchmark Genetics Chief Customer Officer 25-Nov-2024 Bergen, Norway
Hideyoshi Segovia Benchmark Genetics General Manager 25-Nov-2024 Bergen, Norway
Benchmark Genetics Acting Chief Financial Officer 25-Nov-2024 Bergen, Norway
Benchmark Genetics Finance Manager 25-Nov-2024 Bergen, Norway
Benchmark Genetics General Manager 25-Nov-2024 Bergen, Norway

Fund Team Members (48)

Name Investor Fund Fund Location
Robert Ghenchev Novo Holdings Repair Impact Fund Hellerup, Denmark
Robert Ghenchev REPAIR Impact Fund Repair Impact Fund Hellerup, Denmark
Novo Holdings Hellerup, Denmark
REPAIR Impact Fund Hellerup, Denmark
Novo Holdings Hellerup, Denmark

Aleks Engel Ph.D Affiliated Funds (3)

Fund Investor Fund Type Status Vintage Size Dry Powder IRR IRR Quartile
Repair Impact Fund Novo Holdings Venture Capital - Early Stage Closed 2018
Novo Ventures 1 Novo Holdings Venture - General Closed 2013
Novo Seeds Novo Holdings Venture Capital - Early Stage Evergreen

Aleks Engel Ph.D FAQs

  • Who is Aleks Engel Ph.D?

    Dr. Aleks Engel serves as Partner, Planetary Health Investments at Novo Holdings.

  • How much does Aleks Engel Ph.D typically invest?

    Aleks Engel Ph.D's median deal size is .

  • What is Aleks Engel Ph.D’s main position?

    Aleks Engel Ph.D’s primary position is Partner, Planetary Health Investments.

  • How many active board seats does Aleks Engel Ph.D hold?

    Aleks Engel Ph.D holds 2 board seats including Bactolife and Symphogen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »